All Stories

  1. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

    Article • Research and Practice in Thrombosis and Haemostasis, August 2017, Wiley

    Susumu Imazu

  2. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

    Article • British Journal of Clinical Pharmacology, April 2017, Wiley

    Susumu Imazu